Target Healthcare (LON: THRL) financial statements
The consolidated income statement, balance sheet and cash flow statement of Target Healthcare for its last 5 fiscal years, as filed with the regulator, in millions of pounds. At the end of fiscal 2024 it had £986.2m in total assets and £712.5m in equity.
Income statement
| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | £72.9m | £69.6m | £67.7m | £63.9m | £50.0m |
| Finance costs | £11.5m | £11.7m | £10.3m | £6.7m | — |
| Profit before tax | £60.8m | £73.0m | −£6.6m | £49.1m | £43.9m |
| Income tax | £0.0m | £0.0m | £0.0m | £0.0m | −£0.0m |
| Net profit | £60.8m | £73.0m | −£6.6m | £49.1m | £43.9m |
| Earnings per share | £0.0981 | £0.12 | −£0.0106 | £0.082 | £0.0923 |
Balance sheet
| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | £986.2m | £967.4m | £908.3m | £963.7m | £718.4m |
| Current assets | £43.9m | £44.6m | £24.8m | £40.0m | £32.4m |
| Cash | £39.6m | £38.9m | £15.4m | £34.5m | £21.1m |
| Total liabilities | £273.7m | £278.1m | £253.5m | £264.9m | £153.2m |
| Current liabilities | £112.6m | £27.5m | — | — | — |
| Equity | £712.5m | £689.3m | £654.8m | £698.8m | £565.2m |
| Equity including minorities | £712.5m | £689.3m | £654.8m | £698.8m | £565.2m |
Cash flow statement
| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating cash flow | £41.1m | £42.3m | £29.7m | £30.4m | £25.0m |
| Investing cash flow | −£3.2m | £3.4m | −£3.6m | −£202.6m | −£43.6m |
| Financing cash flow | −£37.1m | −£22.2m | −£45.2m | £185.6m | £3.3m |
| Dividends paid | £36.1m | £35.2m | £40.3m | £39.8m | £31.5m |
Where each figure comes from
From the annual report Target Healthcare files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2024 · 2023 · 2022 · 2021. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Target Healthcare page.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.